Patents by Inventor Zdenka L. Jonak
Zdenka L. Jonak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7504102Abstract: This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to the vitronectin ?v?3 receptor and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of ?v?3-mediated disorders, such as restenosis, in human patients.Type: GrantFiled: October 18, 2006Date of Patent: March 17, 2009Assignee: SmithKline Beecham CorporationInventors: Zdenka L Jonak, Kyung O Johanson, Alexander Taylor
-
Publication number: 20080318835Abstract: ITGL-TSP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ITGL-TSP polypeptides and polynucleotides in the design of protocols for the treatment of, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retmopathy), restenosis, Alzheimer's, disease and tissue remodeling, among others, and diagnostic assays for such conditions.Type: ApplicationFiled: February 29, 2008Publication date: December 25, 2008Applicants: Human Genome Sciences, Inc., SmithKline Beecham Corp.Inventors: Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathan A. Terrett, Gregg A. Hastings
-
Publication number: 20080312146Abstract: The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2. Also provided are methods for inhibiting angiogenesis using METH1 or METH2.Type: ApplicationFiled: May 21, 2007Publication date: December 18, 2008Applicants: Human Genome Sciences, Inc., Beth Israel Deaconess Medical Center, SmithKline Beecham Corp.Inventors: Luisa Iruela-Arispe, Gregg A. Hastings, Steven M. Ruben, Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathan A. Terrett
-
Publication number: 20080160576Abstract: This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to the vitronectin ?v?3 receptor and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of ?v?3-mediated disorders, such as restenosis, in human patients.Type: ApplicationFiled: April 25, 2007Publication date: July 3, 2008Inventors: Zdenka L. Jonak, Kyung O. Johanson, Alexander Taylor
-
Patent number: 7230083Abstract: This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to the vitronectin ?v?3 receptor and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of ?v?3-mediated disorders, such as restenosis, in human patients.Type: GrantFiled: August 20, 2002Date of Patent: June 12, 2007Assignee: SmithKline Beecham CorporationInventors: Zdenka L Jonak, Kyung O Johanson, Alexander Taylor
-
Patent number: 7220557Abstract: The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2. Also provided are methods for inhibiting angiogenesis using METH1 or METH2.Type: GrantFiled: August 13, 1999Date of Patent: May 22, 2007Assignees: Human Genome Sciences, Inc., Beth Israel-Deaconess Medical Center, SmithKline Beecham CorporationInventors: Gregg A. Hastings, Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathan A. Terrett
-
Publication number: 20040175794Abstract: ITGL-TSP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed Also disclosed are methods for utilizing ITGL-TSP polypeptides and polynucleotides in the design of protocols for the treatment of, angiogenic diseases (cancer, cancer metasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retinopathy), restenosis, Alzheimer's disease and tissue remodeling, among others, and diagnostic assays for such conditions.Type: ApplicationFiled: January 15, 2004Publication date: September 9, 2004Applicants: Human Genome Sciences, Inc., SmithKline Beecham Corp.Inventors: Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathon A. Terrett, Gregg A. Hastings
-
Publication number: 20040072227Abstract: Human Mindin polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Human Mindin polypeptides and polynucleotides in therapy, and diagnostic assays for such.Type: ApplicationFiled: July 29, 2003Publication date: April 15, 2004Inventors: Zdenka L. Jonak, Stephen H. Trulli, Ping Tsui, Pamela A. Lane
-
Publication number: 20040002449Abstract: The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2. Also provided are methods for inhibiting angiogenesis using METH1 or METH2.Type: ApplicationFiled: November 21, 2001Publication date: January 1, 2004Applicant: Human Genome Sciences, Inc.Inventors: Luisa Iruela-Arispe, Gregg A. Hastings, Steven M. Ruben, Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathan A. Terrett
-
Publication number: 20030166065Abstract: ITGL-TSP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ITGL-TSP polypeptides and polynucleotides in the design of protocols for the treatment of, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retinopathy), restenosis, Alzheimer's disease and tissue remodeling, among others, and diagnostic assays for such conditions.Type: ApplicationFiled: April 4, 2002Publication date: September 4, 2003Applicant: Human Genome Sciences, Inc.Inventors: Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathon A. Terrett, Gregg A. Hastings
-
Publication number: 20030152571Abstract: This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to the vitronectin &agr;v&bgr;3-receptor and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of &agr;v&bgr;3-mediated disorders, such as restenosis, in human patients.Type: ApplicationFiled: August 20, 2002Publication date: August 14, 2003Applicant: SmithKline Beecham CorporationInventors: Zdenka L. Jonak, Kyung O. Johanson, Alexander Taylor
-
Patent number: 5580720Abstract: The present invention provides mammalian cells modified to stably express at least the entire human immunodeficiency virus-1 envelope protein gp160. The invention provides a vaccine comprising the cells of the invention. The invention also provides methods for screening compounds for their ability to inhibit formation of syncytia between cells that express HIV-1 gp160 and cells that express CD4 comprising mixing cells of invention, cells that express CD4 on their surfaces, and a test compound for a length of time sufficient for syncytia to form; and then determining the amount of syncytia formation.Type: GrantFiled: June 2, 1995Date of Patent: December 3, 1996Assignee: SmithKline Beecham CorporationInventors: Zdenka L. Jonak, Christine Debouck, Robert Clark, Stephen Trulli
-
Patent number: 5462872Abstract: The present invention provides mammalian cells modified to stably express at least the entire human immunodeficiency virus-1 envelope protein gp160. The invention provides a vaccine comprising the cells of the invention. The invention also provides methods for screening compounds for their ability to inhibit formation of syncytia between cells that express HIV-1 gp160 and cells that express CD4 comprising mixing cells of invention, cells that express CD4 on their surfaces, and a test compound for a length of time sufficient for syncytia to form; and then determining the amount of syncytia formation.Type: GrantFiled: October 8, 1993Date of Patent: October 31, 1995Assignee: SmithKline Beecham CorporationInventors: Zdenka L. Jonak, Christine Debouck, Robert Clark, Stephen Trulli
-
Patent number: 4652522Abstract: A method for producing continuous B lymphocyte cell lines and monoclonal antibodies by such lines is provided. DNA isolated from neoplastic cells is introduced into stimulated lymphocytes. Individual cells that have been transformed by the added DNA and that produce antibodies are clonally expanded. Cultures of these continuous cells are employed to produce monoclonal antibodies.Type: GrantFiled: July 5, 1983Date of Patent: March 24, 1987Assignee: The University of PennsylvaniaInventors: Roger H. Kennett, Zdenka L. Jonak